JPM26: BioNTech gears up for multiproduct oncology status by 2030 [Yahoo! Finance]
Bristol-Myers Squibb Company (BMY)
Last bristol-myers squibb company earnings: 2/6 07:05 am
Check Earnings Report
US:NYSE Investor Relations:
bms.com/investors.html
Company Research
Source: Yahoo! Finance
Speaking at the J.P. Morgan Healthcare Conference in San Francisco, taking place from 12 to 15 January, BioNTech CEO Ugur Sahin said: “Our ambition is to build a fully integrated multiproduct oncology company, and 2026 is just the beginning of our road map.” BioNTech became a well-established company in the pharmaceutical sector after co-developing the first mRNA Covid-19 vaccine with Pfizer. Amid waning demand for Covid-19 products, however, BioNTech's share price is currently trading around 77% lower compared to its all-time high share price in August 2021. While the Germany-headquartered company will still make adaptive Covid-19 vaccines as new infectious seasons arrive, Sahin is overseeing a significant strategic pivot to oncology in a bid to boost revenues. BioNTech currently has more than 25 Phase II and III programmes across oncology and 10 novel-combination trials. Modalities in its cancer pipeline include next generation immunomodulators, antibody drug conjugates (ADCs
Show less
Read more
Impact Snapshot
Event Time:
BMY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BMY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BMY alerts
High impacting Bristol-Myers Squibb Company news events
Weekly update
A roundup of the hottest topics
BMY
News
- Central Nervous System Therapeutic Market Report 2025-2033: Key Drivers, Regional Nuances, Competitive Dynamics | Astute Analytica [Yahoo! Finance]Yahoo! Finance
- Bristol-Myers Squibb Reports Positive Phase 3 SCOUT-HCM Results for Camzyos in Adolescent Patients [Yahoo! Finance]Yahoo! Finance
- Healthy Returns: Novo Nordisk CEO on GLP-1 pricing, and more insights from the JPM conference [CNBC]CNBC
- [Latest] Global T-Cell Engagers Market Size/Share Worth USD 18.8 Billion by 2034 at a 21.2% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis) [Yahoo! Finance]Latest
- What You Need To Know Ahead of Bristol-Myers Squibb's Earnings Release [Yahoo! Finance]Yahoo! Finance
BMY
Earnings
- 10/31/25 - Beat
BMY
Sec Filings
- 1/12/26 - Form 8-K
- 1/5/26 - Form 4
- 1/5/26 - Form 4
- BMY's page on the SEC website